Please join us in congratulating our undergraduate lab members Maya Chandar, Anna Corcoran, Will McIntosh, and Elise Nackley on their graduation this past Friday. Our lab is very proud of their hard work and excited to celebrate this important milestone with them. As they move on to the next phase of their journey, we wish […]
Lab members sharing discoveries and representing our mission at the 2026 AAI and AACR conferences, helping shape the future of cancer and immunotherapy research
The TIL Team proudly running in the 2026 Angels Among Us fundraising event to advance hope, research, and better treatments for patients with brain tumors.
April 16, 2026 While immunotherapy has been a remarkable success in the treatment of several tumor types, establishing its effectiveness in the central nervous system (CNS) tumor space has been challenging, particularly for glioblastoma (GBM) patients. Several factors are thought to contribute to this lack of progress including the blood-brain barrier limiting penetration of systemic […]
Click here for recent news on the approval of vorasidenib for IDH mutated gliomas: https://www.youtube.com/watch?v=1_9cb-Egbro
The Khasraw lab is proud to share that several abstracts have been selected for platform presentations at the 2026 annual meetings of the American Association of Immunology (AAI) and the American Association for Cancer Research (AACR). At AAI, congratulations to Kelly Hotchkiss for receiving an award for her presentation on the ETAPA clinical trial, and […]
Join us in congratulating our very own Kelly Hotchkiss and Elizabeth Owens for receiving the 2026 AAI Trainee Abstract Award! This award recognizes outstanding contributions from early-career scientists and provides recipients with registration to IMMUNOLOGY2026™, where Kelly and Elizabeth will present their research in a Block Symposium oral session. Being selected is a significant achievement […]
February 14, 2026 The long-awaited GIANT clinical trial which aims to determine whether the combination of immunotherapy drugs (Nivolumab and Relatlimab) with conventional treatment can meaningfully improve outcomes for glioblastoma patients, has officially been launched in the US. The trial will involve multiple cancer centers and use a two-stage approach: first assessing safety in a […]
January 28, 2026 Scientists have identified a small molecule called compound A that shrinks glioblastoma brain tumors in mice by targeting advillin (AVIL), a protein found at abnormally high levels in this aggressive cancer. Because AVIL regulates the cell’s actin cytoskeleton and lacks obvious drug-binding sites, it was long considered an extremely difficult target, but […]
Wishing everyone a happy holiday season and a happy new year!